Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients

In clinical trials and meta-analysis, atherosclerotic vascular events (AVEs) during treatment with immune-checkpoint inhibitors (ICIs) have been reported with low incidence. However, preclinical data suggest that these drugs can promote atherosclerosis inflammation and progression of atherosclerosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Inno, Alessandro, Chiampan, Andrea, Lanzoni, Laura, Verzè, Matteo, Molon, Giulio, Gori, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193098/
https://www.ncbi.nlm.nih.gov/pubmed/34124192
http://dx.doi.org/10.3389/fcvm.2021.652186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193098/
https://www.ncbi.nlm.nih.gov/pubmed/34124192
http://dx.doi.org/10.3389/fcvm.2021.652186

Ejemplares similares